Recorded device evidence

Ultrast Gel (K211691): indications, design and recorded evidence

The acquired K211691 file contains product-specific indications and users, design and operating principle, non-clinical evidence actually described, clinical evidence or its stated absence sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 5 selected decisions under primary code MUI. 5 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

No quartiles are displayed: this complete-year cohort has fewer than 20 valid pairs.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K211691 ↗ · this pageUltrast Gel2021-06-02 → 2021-12-22203Traditional
K253255 ↗Non-Sterile Ultrasound Gel Sterile Ultrasound Gel2025-09-29 → 2026-06-17261Traditional
K252337 ↗EdgeFlow Gel Pad2025-07-28 → 2026-04-24270Traditional
K242167 ↗Sterile and Non-Sterile Ultrasonic Coupling Agent2024-07-24 → 2024-09-1957Traditional
K241789 ↗Non-Sterile Ultrasound Transmission Gels2024-06-21 → 2024-07-2433Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K211691 · PDF page 5 ↗ Source 2

Ultrast Gel is an in vivo biocompatible and bioexcretable sterile couplant intended for use as a
scanning gel in surgical procedures, biopsies and similar sterile applications.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K211691 · PDF page 4 ↗ Source 3

The Ultrast Gel device, manufactured for Ultrast, Inc. is a phase changing hydrogel ultrasound
coupling agent comprised of hydroxy-propylcellulose, sodium chloride, sodium citrate, and
water.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Non-clinical evidence actually described

K211691 · PDF page 8 ↗ Source 4

To establish the substantial equivalence of Ultrast Gel, bench testing was conducted to validate
the performance of the device.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

Clinical evidence or its stated absence

K211691 · PDF page 9 ↗ Source 5

Not applicable.  Clinical studies are not necessary to establish the substantial equivalence of this
device.

Compare with your product: Preserve whether the summary describes clinical evidence or says none was performed. This recorded case does not determine whether your product needs clinical evidence.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK211691 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryUltrast Gel [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantUltrast, Inc. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeMUI [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2021-12-22 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2021-06-02 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Non-clinical evidence actually described — what differs in our product?

    Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

    Useful evidence: Existing protocols/results and design-specific evidence gaps, with standard editions and scope reviewed separately.

  4. Clinical evidence or its stated absence — what differs in our product?

    Preserve whether the summary describes clinical evidence or says none was performed. This recorded case does not determine whether your product needs clinical evidence.

    Useful evidence: Your proposed claims and supporting evidence, plus a reviewed rationale for clinical-evidence needs.

Work packages and dependencies

What needs to happen first

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[99992] · record a60bfdf5668e76ec74051c075b608ef874ab26813d50f47a759e4d22d42d6644
  • [6] Complete results array / fda-decision-context:K211691 · record whole dataset partition

FDA 510(k) summary — K211691 ↗

Fri, 24 Dec 2021 01:00:12 GMT · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot a91393b0a4e7587ad1472d3be7c2b2b277dd049fcf9b7e426ef92b96a127a29f

  • [2] PDF page 5 · record 945e4ea4e0ef658ee0f94f8ca6038332dea336283e810302f4cf7da68a7a54dd
  • [3] PDF page 4 · record d17cf5eef37c07d868be02821518dfd9cc6a48e41b30a07f5908b9a3335936f7
  • [4] PDF page 8 · record f636b8c608d421c5dbb3be5bf753a0c1908c50c133427b119aae5998e836a15c
  • [5] PDF page 9 · record 4e5e6753ff16a32bdee8ce661f20839894c904fbfd34f5d0ab08c830d02824f0

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services

Biocompatibility Testing (ISO 10993 Program) · Medical Device Cybersecurity